MedPath

Trifluoperazine Effectiveness in Treatment of Coronavirus

Phase 2
Recruiting
Conditions
COVID-19.
?????? ??? ?????
J00-J99
Registration Number
IRCT20200329046892N1
Lead Sponsor
Rasht University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
70
Inclusion Criteria

?All of the patients admitted to Razi hospital of Rasht and diagnosed for COVID-19 in April-March 2020
18 years old and more
?Fever (oral temperature more than 37.8)
At least one of the following criteria
Respiratory rate 24 and more per minute
At rest SPO2 fewer than 94
PCR positive
Pulmonary involvement in CT or chest X-ray

Exclusion Criteria

Those who aren't willing to participate in the study based on personal satisfaction
concomitant use of an anti-psychotic drug
History of epileptic disorders
Parkinson's Disease
Dementia
Symptomatic hepatic dysfunction
Allergic reaction to Phenothiazines
History of pheochromocytoma
Any major drug-interaction between routine-taken drugs with trifluoperazine
Pregnancy and breastfeeding
Previous COVID-19 treatment
Multi-organ failure evidences
Need to mechanical ventilation on entrance to the study
eGFR< 50 mL/min

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath